Skip to main content
Tetra Bio-Pharma Inc. logo

Tetra Bio-Pharma Inc. — Investor Relations & Filings

Ticker · TBPMQ ISIN · CA88166Y1007 LEI · 5299000CYH3P8XC2UO53 TSX Manufacturing
Open in API
Filings indexed 720 across all filing types
Latest filing 2020-05-26 Capital/Financing Update
Country CA Canada
Listing TSX TBPMQ

About Tetra Bio-Pharma Inc.

https://tetrabiosciences.com/

Tetra Bio-Pharma is a biopharmaceutical company specializing in the discovery and development of cannabinoid-derived drugs and medicinal plant-based products. The company maintains an advanced pipeline encompassing biopharmaceuticals, natural health, and veterinary products. Clinical programs are focused on therapeutic areas such as inflammation, pain management (including alternatives to opioids), and ophthalmology. Tetra emphasizes rigorous clinical trials and scientific evidence, utilizing novel approaches, unique mechanisms of action, and high-quality delivery methods to address unmet patient needs.

Recent filings

Filing Released Lang Actions
Material change report - English.pdf
Capital/Financing Update Classification · 95% confidence The document is titled 'FORM 51-102F3 MATERIAL CHANGE REPORT' and details a material change event dated May 22, 2020. It describes the closing of a public overnight marketed offering of units, including the exercise of an over-allotment option, with specifics on the number of units sold, pricing, and use of proceeds. The document is a regulatory filing reporting a material change event related to financing activities. It is not a full financial report, earnings release, or management discussion. The content aligns with a Capital/Financing Update as it provides detailed information on a financing transaction and its terms. The document length (6278 characters) supports it being a substantive report rather than a brief announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-05-26 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the granting of a new foreign patent by Tetra Bio-Pharma. It discusses intellectual property developments, specifically a new Australian patent related to ophthalmic pharmaceutical compositions. There is no financial data, no mention of financial results, no regulatory filings, no shareholder meeting information, no management changes, no earnings data, and no detailed report content. The document is a corporate announcement about intellectual property and patent status, which does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is a general corporate news announcement about patent and IP portfolio updates. Given the filing categories, the best fit is Regulatory Filings (RNS) as a general regulatory announcement or corporate news that does not fit other specific categories. The document length is moderate and contains no indication of being a report or formal filing but rather a news release. Confidence is high due to clear content and lack of financial or regulatory report elements.
2020-05-26 English
Other securityholders documents - English.pdf
Capital/Financing Update Classification · 95% confidence The document is titled 'Warrant Indenture' and details the terms and conditions related to the issuance of common share purchase warrants by Tetra Bio-Pharma Inc. It includes detailed articles on interpretation, issue of warrants, exercise of warrants, covenants, enforcement, meetings of warrantholders, and other legal and procedural provisions. This is a legal contract governing the rights and obligations related to warrants, not a financial report, earnings release, or management discussion. It is not an announcement or summary but a full legal indenture document. Therefore, it fits best under the category of Capital/Financing Update (CAP), as it relates to the company's capital structure and financing instruments (warrants).
2020-05-26 English
News release - English.pdf
Capital/Financing Update Classification · 100% confidence The document is a press release announcing the closing of a public offering by Tetra Bio-Pharma Inc. It details the number of units sold, the price, the use of proceeds, and the agents involved. It references the base shelf prospectus and prospectus supplement filed on SEDAR but does not contain any financial statements or detailed financial analysis. The document is focused on financing activity, specifically the completion of a capital raise through a public offering. It is not an annual report, earnings release, or any other type of financial report. Given the content and purpose, this document fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing event, not just an announcement of a report publication or a regulatory filing. Therefore, the classification is CAP with high confidence.
2020-05-22 English
Consent letter of issuer's legal counsel.pdf
Regulatory Filings Classification · 95% confidence The document is a letter of consent from a legal firm regarding a Prospectus Supplement related to an offering of Units by Tetra Bio-Pharma Inc. It is addressed to multiple securities commissions and references legal opinions and the Prospectus Supplement dated May 19, 2020. The content is focused on legal consent and opinions related to a financing document (Prospectus Supplement), not the financial report or the prospectus itself. The document length is short (1742 characters), and it does not contain financial data or detailed report content. Therefore, it is best classified as a Regulatory Filing (RNS), which covers legal opinions and miscellaneous regulatory documents that do not fit other categories.
2020-05-20 English
Auditors' consent letter.pdf
Regulatory Filings Classification · 95% confidence The document is a letter from the auditor (McGovern Hurley LLP) providing consent for the use of their audit report in a prospectus supplement related to a securities offering by Tetra Bio-Pharma Inc. It references the audit report dated March 25, 2020, on the financial statements for the years ended November 30, 2019 and 2018. The letter states that the auditor has read the prospectus supplement and consents to the use of their report but clarifies that this consent does not constitute an audit or review of the prospectus supplement itself. The document is short (2244 characters) and is primarily an auditor's consent letter, not the audit report itself or the full financial statements. According to the Certification Rule and the Menu vs Meal Rule, such a document should be classified as a Regulatory Filing (RNS) because it is an auditor's consent letter related to a prospectus supplement, not the audit report or the prospectus supplement itself.
2020-05-20 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.